1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nova Eye Medical Limited

Nova Eye Medical Limited

ELXMF
Nova Eye Medical LimitedUS flagOther OTC
0.01
USD
- -
- -
4.08MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.49
0.49
0.57
0.65
0.59
0.57
0.55
0.09
0.09
0.09
0.11
0.11
0.12
Basic EPS, GAAP
-0.01
0.01
0.02
0.03
-0.01
-0.04
-0.04
0.24
-0.03
-0.05
-0.1
-0.04
-0.04
Free Cash Flow per Basic Share
0.01
0.01
0.04
- -
-0.09
-0.02
-0.01
-0.01
-0.01
-0.03
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.13
- -
- -
- -
- -
Book Value per Share
0.37
0.35
0.37
0.43
0.48
0.54
0.46
0.7
0.25
0.21
0.15
0.11
0.08
Tangible Book Value per Share
0.34
0.3
0.32
0.39
0.44
0.52
0.44
0.66
0.22
0.16
0.09
0.07
0.05
Basic Weighted Avg Shares
87
111
111
112
121
138
147
147
148
149
160
204
247
Sales/Revenue/Turnover
43
54
63
73
72
79
82
13
13
14
17
23
29
Operating Margin (%)
-0.61
3.54
3.46
8.68
0.25
-7.07
-7.79
-56.19
-38.58
-71.15
-70.45
-38.45
-38.43
Depreciation Expense
1
1
3
3
3
2
2
1
2
2
2
3
2
Net Income, GAAP
-1
1
2
3
-1
-5
-6
36
-4
-7
-15
-9
-9
Effective Tax Rate (%)
682.86
39.89
36.15
27.76
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1.91
1.45
2.68
4.15
-1.25
-6.37
-7.07
279.22
-32.52
-54.99
-89.83
-37.68
-30.95
Working Capital
11
15
18
24
20
41
28
89
22
12
8
9
7
LT Debt
1
1
1
2
- -
6
- -
1
2
1
1
3
2
Total Equity
31
37
40
48
57
75
69
101
35
30
23
21
19
Return on Invested Capital (%)
3.87
2.86
3.1
8.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-5.97
2.22
3.9
6.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-2.5
2.21
4.21
6.77
-1.68
-7.6
-8.13
41.92
-6.2
-21.92
-56.52
-38.81
-43.95

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.26%
-24.33%
-11.08%
Free Cash Flow
1,272.03%
47.03%
-5.12%
Net Income, GAAP
-26.45%
4.88%
3.06%
Sales/Revenue/Turnover
3.79%
18.81%
25.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
17
2024
- -
- -
- -
- -
23
2025
- -
- -
- -
- -
29

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.1
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Tom Spurling
Full Time Employees
301
Sector
Healthcare
Industry
Medical - Devices
Address
107 Rundle Street Kent Town SA Australia 5067
IPO Date
Jan 20, 2010
Website
nova-eye.com
Similar Companies
Sight Sciences, Inc. (SGHT)
Senzime AB (publ) (SNZZF)
Medinice S.A. (ICE.WA)
BICO Group AB (publ) (BICO.ST)
Hylsamex S.A. de CV (HYLSAMXB.MX)
Medtronic plc (MDT)
Business
Nova Eye Medical Limited designs, develops, manufactures, markets and sells proprietary surgical devices and technologies primarily for glaucoma treatment and related ophthalmic conditions. The company offers the iTrack family of canaloplasty microcatheters, including iTrack and iTrack Advance, which restore the eye's natural outflow pathway to reduce intraocular pressure in patients with mild to moderate open-angle glaucoma without stents or tissue removal; the Molteno3 glaucoma drainage device platform for severe and complex glaucoma cases, providing simplified surgical procedures and long-term intraocular pressure control; and the 2RT laser technology for early and intermediate age-related macular degeneration and diabetic retinopathy. Incorporated in 1970 and headquartered at 107 Rundle Street in Kent Town, South Australia, Nova Eye Medical operates sales headquarters in Fremont, California, with manufacturing facilities in Fremont and Dunedin, New Zealand, and serves eye surgeons in over 100 countries across the United States, Europe, Asia Pacific including China, Australia and other international markets through direct sales teams and a global network of distribution partners. Formerly known as Ellex Medical Lasers Limited, the company changed its name to Nova Eye Medical Limited in July 2020 following the divestment of its lasers and ultrasound business to Lumibird Group SA in June 2020. Recent developments include National Medical Products Administration approval for iTrack Advance in China in September 2025 to expand sales in that market; global sales excluding China of US$4.9 million in the quarter ended September 2025, up 32% year-over-year, with last 12 months revenue exceeding A$30 million; reaffirmed FY26 sales guidance excluding China of US$21-24 million and expectation of EBITDA breakeven in the second half of FY26; a A$488,000 grant award in July 2025 with Adelaide University for quantum technology in early eye disease detection; and ongoing evaluation of iTrack microcatheter for targeted ocular drug delivery with pharmaceutical partners.

Company News

APIChatGPT

  • seekingalpha.com

    Nova Eye Medical Limited (ELXMF) Q3 2026 Earnings Call Transcript

  • seekingalpha.com

    Nova Eye Medical Limited (ELXMF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Nova Eye Medical Limited (ELXMF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Nova Eye Medical Limited (ELXMF) Q2 2026 Sales/Trading Call Transcript

  • seekingalpha.com

    Nova Eye Medical Limited (ELXMF) Discusses Clinical Insights and Practice Advantages of iTrack Advance Glaucoma Device Prepared Remarks Transcript